Cargando…

Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?

BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tacyildiz, Nurdan, Tanyildiz, Hikmet Gulsah, Dincaslan, Handan Ugur, Yavuz, Gulsan, Unal, Emel, Ozkan, Elgin, Soydal, Cigdem, Kucuk, Ozlem, Yildiz, Yusuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904339/
https://www.ncbi.nlm.nih.gov/pubmed/27307968
http://dx.doi.org/10.5812/ijp.4008
_version_ 1782437129790423040
author Tacyildiz, Nurdan
Tanyildiz, Hikmet Gulsah
Dincaslan, Handan Ugur
Yavuz, Gulsan
Unal, Emel
Ozkan, Elgin
Soydal, Cigdem
Kucuk, Ozlem
Yildiz, Yusuf
author_facet Tacyildiz, Nurdan
Tanyildiz, Hikmet Gulsah
Dincaslan, Handan Ugur
Yavuz, Gulsan
Unal, Emel
Ozkan, Elgin
Soydal, Cigdem
Kucuk, Ozlem
Yildiz, Yusuf
author_sort Tacyildiz, Nurdan
collection PubMed
description BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor were affected by these treatments and to determine the importance of the 18F-FDG PET method. PATIENTS AND METHODS: Twenty metastatic bone tumor cases were included. Sorafenib and anti-VEGF were added to the standard treatment in cases with widespread metastatic disease at diagnosis or after neoadjuvant chemotherapy showing less than 90% tumor necrosis in the surgical sample. Positron emission tomography (PET) imaging was performed at diagnosis, the preoperative period following neoadjuvant chemotherapy, during postoperative follow-up, and when treatment was discontinued. RESULTS: The primary treatment region median SUVmax level decreased from 7.35 to 2.5 in the living patients (n = 16) while there was no significant decrease in the patients who succumbed to the disease (P < 0.001). Comparison of the pre- and post-treatment metastasis region median SUVmax levels in patients with metastatic involvement showed a decrease from 2.1 to 0 in the surviving patients but only from 4.8 to 3.2 in the deceased patients (P < 0.01). Survival results indicated that 28.6% of the patients receiving classical treatment only died while all the patients receiving additional sorafenib and anti-VEGF survived. CONCLUSIONS: 18F-PET may be a useful technique before and during the follow-up of neoadjuvant treatment in pediatric metastatic bone tumor patients. The addition of sorafenib and anti-VEGF to classical treatment has a favorable contribution to the response and therefore the survival duration.
format Online
Article
Text
id pubmed-4904339
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-49043392016-06-15 Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? Tacyildiz, Nurdan Tanyildiz, Hikmet Gulsah Dincaslan, Handan Ugur Yavuz, Gulsan Unal, Emel Ozkan, Elgin Soydal, Cigdem Kucuk, Ozlem Yildiz, Yusuf Iran J Pediatr Research Article BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor were affected by these treatments and to determine the importance of the 18F-FDG PET method. PATIENTS AND METHODS: Twenty metastatic bone tumor cases were included. Sorafenib and anti-VEGF were added to the standard treatment in cases with widespread metastatic disease at diagnosis or after neoadjuvant chemotherapy showing less than 90% tumor necrosis in the surgical sample. Positron emission tomography (PET) imaging was performed at diagnosis, the preoperative period following neoadjuvant chemotherapy, during postoperative follow-up, and when treatment was discontinued. RESULTS: The primary treatment region median SUVmax level decreased from 7.35 to 2.5 in the living patients (n = 16) while there was no significant decrease in the patients who succumbed to the disease (P < 0.001). Comparison of the pre- and post-treatment metastasis region median SUVmax levels in patients with metastatic involvement showed a decrease from 2.1 to 0 in the surviving patients but only from 4.8 to 3.2 in the deceased patients (P < 0.01). Survival results indicated that 28.6% of the patients receiving classical treatment only died while all the patients receiving additional sorafenib and anti-VEGF survived. CONCLUSIONS: 18F-PET may be a useful technique before and during the follow-up of neoadjuvant treatment in pediatric metastatic bone tumor patients. The addition of sorafenib and anti-VEGF to classical treatment has a favorable contribution to the response and therefore the survival duration. Kowsar 2016-03-05 /pmc/articles/PMC4904339/ /pubmed/27307968 http://dx.doi.org/10.5812/ijp.4008 Text en Copyright © 2016, Growth & Development Research Center http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Tacyildiz, Nurdan
Tanyildiz, Hikmet Gulsah
Dincaslan, Handan Ugur
Yavuz, Gulsan
Unal, Emel
Ozkan, Elgin
Soydal, Cigdem
Kucuk, Ozlem
Yildiz, Yusuf
Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title_full Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title_fullStr Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title_full_unstemmed Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title_short Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
title_sort can fluorine-18-fluorodeoxyglucose positron emission tomography be used as a useful method to evaluate the treatment response to neoadjuvant therapy combined with sorafenib and anti-vegf in children diagnosed with metastatical bone sarcoma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904339/
https://www.ncbi.nlm.nih.gov/pubmed/27307968
http://dx.doi.org/10.5812/ijp.4008
work_keys_str_mv AT tacyildiznurdan canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT tanyildizhikmetgulsah canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT dincaslanhandanugur canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT yavuzgulsan canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT unalemel canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT ozkanelgin canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT soydalcigdem canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT kucukozlem canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma
AT yildizyusuf canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma